Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer.

ABSTRACT:

Background

Novel human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugates prompt the identification of the HER2-low subtype. However, the biological significance of HER2-low expression in breast cancer is unclear.

Methods

Clinical and genomic data of 579 metastatic breast cancer patients were reviewed from our next-generation sequencing (NGS) database and genomic analysis of early breast cancer patients from TCGA was also analyzed.

Findings

First, the clinicopathological characteristics of HER2-low patients were profoundly influenced by HR status and no difference of prognosis was observed between HER2-low and HER2-zero patients when paired by HR status, but notably HER2-low patients showed similar metastatic patterns to HER2-positive patients

SUBMITTER: Jin J 

PROVIDER: S-EPMC10236705 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature